SCHEMBL1946326

SCHEMBL1946326

CC(=O)N1C(=O)/C(=C(/O)c2ccc(CCC(=O)O)cc2)c2ccc(F)cc21

nearest known ligand 0.42

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 12/20 0.42
FFAR4 Q5NUL3 9/20 0.42
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
PPARG P37231 1/20 0.39
PLA2G4A P47712 2/20 0.36
HSD17B10 Q99714 1/20 0.36
KEAP1 Q14145 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1946329 1.00 FFAR1 (0.42) FFAR1FFAR4PPARDPPARAPPARG
SCHEMBL3532597 0.90 PTPN1 (0.39) FFAR1FFAR4
SCHEMBL3532600 0.90 PTPN1 (0.39) FFAR1FFAR4
SCHEMBL3666573 0.89 FFAR4 (0.40) FFAR1FFAR4PPARDPPARAPPARG
SCHEMBL3666575 0.89 FFAR4 (0.40) FFAR1FFAR4PPARDPPARAPPARG
SCHEMBL1943746 0.88 CYP4F2 (0.41) FFAR1FFAR4HSD17B10
SCHEMBL1943744 0.88 CYP4F2 (0.41) FFAR1FFAR4HSD17B10
SCHEMBL3530434 0.86 RAB9A (0.41) HSD17B10
SCHEMBL3530430 0.86 RAB9A (0.41) HSD17B10
SCHEMBL3527978 0.83 L3MBTL1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2238108-B1 SALT FORMS OF A 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE DERIVATIVE, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME BOEHRINGER INGELHEIM INT (DE) 2012-08-29 EP disclosed
US-20110130437-A1 SALT FORMS OF A 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE DERIVATIVE, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-06-02 US disclosed
US-20110046395-A1 PROCESS FOR THE MANUFACTURE OF A 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE DERIVATIVE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-24 US disclosed
EP-2238108-A1 SALT FORMS OF A 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE DERIVATIVE, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Boehringer Ingelheim International GmbH (DE) 2010-10-13 EP disclosed
EP-2238107-A1 PROCESS FOR THE MANUFACTURE OF A 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE DERIVATIVE Boehringer Ingelheim International GmbH (DE) 2010-10-13 EP disclosed
WO-2009092580-A1 PROCESS FOR THE MANUFACTURE OF A 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE DERIVATIVE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-07-30 WO disclosed
WO-2009092581-A1 SALT FORMS OF A 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE DERIVATIVE, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046395-A1 PROCESS FOR THE MANUFACTURE OF A 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE DERIVATIVE FDPS, DHPS, UGT1A6 FFAR1 1072/4885FFAR4 648/4885PPARD 1571/4885
US-20110130437-A1 SALT FORMS OF A 6-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE DERIVATIVE, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC5A11, CYP2D6 FFAR1 1035/4885FFAR4 687/4885PPARD 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.